Accenture plc (ACN) Pops 3.83% for January 22

Equities Staff  |

One of the S&P 500’s big winners for Friday January 22 was Accenture plc (ACN) as the company’s stock climbed 3.83% to $102.05 on volume of 2.59 million shares.

The stock opened at $99.79 and saw an intraday low of $99.56 and an intraday high of $102.26. All told, the day saw a per-share gain of $3.76. The stock’s average daily volume of 2.67 million and 650.93 million shares outstanding. Accenture plc now has a 50-day SMA is $104.59 and 200-day SMA is $99.55, and it has a 52-week high of $109.86 and a 52-week low of $83.47.

Accenture PLC is a professional service company. The Company is engaged in providing management consulting, technology and outsourcing services to clients.

Based out of Dublin, , Accenture plc has 358,000 employees and, after today’s trading, reached a market cap of $66.43 billion. The stock’s P/E Ratio is 20.7. Its P/S ratio is 1.94, P/B ratio is 11.26, and P/FCF ratio is 101.3.

For a complete fundamental analysis analysis of Accenture plc, check out’s Stock Valuation Analysis report for ACN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…